According to the findings presented above, certain people suffering from advanced NSCLC with EGFR 20 insertional mutations may benefit from afatinib medication in the first line and further on, and disease control can even last for more than 3 years. This evidence concerns the gene EGFR and non-small cell lung carcinoma.